Clinical trials: Non-standard Therapy
COVID-19
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
Tocilizumab is an effective treatment for severe coronavirus disease 2019 (Covid-19) pneumonia and related inflammation. Given limited global supplies, clarification of the optimal tocilizumab dose is critical.
- Trial name
- COVIDOSE-2 (NCT04479358)
- Testing
- Tocilizumab, Standard of Care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
COPD Exacerbation
Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care
Objective: To evaluate non-inferiority of Trimbow, an approved therapy for treatment of severe COPD, in ICU compared to the standard of care which is based on the same therapeutic approach.
- Trial name
- TRIMICU (NCT04737655)
- Testing
- TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation
- Volunteers
- 200 people
- Sponsor
- PARZIBUT Gilles
Solid Cancers
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered once daily (QD) and twice daily (BID) in the treatment of…
- Trial name
- NCT00876109
- Testing
- GDC-0941
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Genentech, Inc.
Standard Therapy, Non-standard Therapy
SD vs. NSD Therapy in Elderly AML
It is known that treatment outcome could be positively associated with treatment intensity. However, tolerance of chemotherapy decreases in the elder, some patients could not tolerate standard (SD) therapy and even died of side…
- Trial name
- NCT03733834
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Staphylococcus
Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.
Evaluate the efficacy of a sequential regimen of 14 days in patients with catheter-related bacteremia by S. aureus methicillin-susceptible, selected based on a pre-established clinical and microbiological criteria.
- Trial name
- NCT01875263
- Testing
- Cloxacilin, Cloxacillin, Levofloxacin
- Where
- 11 sites in Spain
- Volunteers
- 1 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Age-Related Macular Degenerations., Subfoveal Neovascularization.
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
A compassionate method of treatment is offered to patients where lesions do not meet acceptable criteria for standard therapy. Visudyne (Photodynamic Therapy) and laser photocoagulation treatment (a treatment using heat from a…
- Trial name
- NCT00211484
- Testing
- Anecortave Acetate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Hypogammaglobulinemia, Bacterial Infections
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in…
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
- Trial name
- EXCELL (NCT05645107)
- Testing
- Xembify
- Where
- 62 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 386 people
- Sponsor
- Grifols Therapeutics LLC
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India.
- Trial name
- NCT07881835
- Testing
- Elranatamab
- Volunteers
- 75 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
To assess the efficacy and feasibility of high-dose intensity-modulated radiotherapy with concurrent weekly paclitaxel and cisplatin for patients with locoregionally advanced non-small lung cancer.
- Trial name
- NCT03598517
- Testing
- high dose chemoradiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Metastatic Non Small Cell Lung Cancer
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
This clinical trial is comparing morning infusions of the study drug (pembrolizumab) to random infusion scheduling for patients with non-small cell lung cancer.
- Trial name
- TIME-NSCLC (NCT06882174)
- Testing
- Scheduling of the time of pembrolizumab infusions
- Volunteers
- 58 people
- Sponsor
- AHS Cancer Control Alberta
Carcinoma, Non-Small-Cell Lung
Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments
This is a multicenter, prospective, single-arm clinical study to determine the efficacy and safety of Drug-eluting beads bronchial arterial chemoembolization（DEB-BACE） in stage II-III NSCLC patients who failed, refused or…
- Trial name
- NCT04825925
- Testing
- DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Non Small Cell Lung Cancer Stage
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18…
- Trial name
- NCT04992780
- Testing
- Hypo-Fractionation, Standard-Fractionation
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Kansas Medical Center
Non-Small Cell Lung Cancer
A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients
Primary objective: ● To evaluate the efficacy of pemigatinib in advanced non-small cell lung cancer patients with fibroblast growth factor receptor 1-3 (FGFR 1-3) alterations (including but not limited to FGFR amplification…
- Trial name
- NCT05210946
- Testing
- Pemigatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Gastrointestinal Stromal Tumors
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Activating mutations of the kinases CKIT or PDGFRA can be detected in 90% of cases by DNA sequence analysis of a pathological specimen.
- Trial name
- NCT01462994
- Testing
- Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Technical University of Munich
Neoplasms
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus…
- Trial name
- NCT06926673
- Testing
- Dostarlimab, Belrestotug., Nelistotug
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 62 people
- Sponsor
- GlaxoSmithKline
Non Metastatic Breast Cancer
The Impact of Oncoplastic Breast Surgery on the Oncological Safety and Patient Satisfaction
The aim of this study is to asses the oncological safety of oncoplastic breast surgery, its impact on patient satisfaction and is it worthy for general breast surgeon to learn different oncoplastic techniques.
- Trial name
- NCT02901223
- Testing
- Standard quadrantectomy, oncoplastic breast surgery
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Blood Loss, Surgical
Observational Cohort Study of TachoSil (TC-018-IN)
The purpose of this study is to collect information, after exposure to TachoSil ®, of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding.
- Trial name
- NCT00285623
- Testing
- Fibrinogen (human) + thrombin (human) (TachoSil)
- Where
- Denmark
- Volunteers
- 3,000 people
- Sponsor
- Nycomed
Non-small Cell Lung Cancer
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small…
- Trial name
- EVIDENCE (NCT02448797)
- Testing
- Icotinib, Chemotherapy
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Neoplasms (Locally Advanced Non-metastatic)
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas.
- Trial name
- SCALOP-2 (NCT02024009)
- Testing
- nab-paclitaxel, 60Gy in 30#, 50.4Gy in 28#
- Where
- 23 sites in United Kingdom
- Volunteers
- 159 people
- Sponsor
- University of Oxford